| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3193716 | Annals of Allergy, Asthma & Immunology | 2007 | 7 Pages |
Abstract
Angioedema attributable to an ACE-I or ARB resolves on discontinued use of the medication. It most commonly affects women and African Americans and did so in the first month of treatment in 25% of patients. Physicians should be aware but not deterred necessarily from recommending an ARB in patients with ACE-I-induced angioedema because of the benefits of control of hypertension or reducing albuminuria in selected patients.
Related Topics
Health Sciences
Medicine and Dentistry
Dermatology
Authors
Baiju MD, Jane PharmD, Paul A. MD,